strong launch us increas estim
aurobindo soft major launch us
howev start stronger expect
increas ep reflect
expect sequenti increas us sale
mn qoq support recent launch name
ertapenem reyataz vancomycin omeprazol
over-the-counter current auro gener ertapenem
make mn per quarter absenc competit
steadi state ertapenem could reduc mn annual
howev low competit period least continu
reyataz posit surpris limit competit far auro
third gener vancomycin contribut mn annual
launch over-the-counter auro alreadi launch omeprazol
tab potenti contribut mn annual
catalyst beyond toprol approv octob
restart inject bag line ibuprofen over-the-counter
launch mn opportun valuat
attract pe maintain outperform
estimate pot chg tp
 chang prev ep
note aurobindo pharma pharma compani india cater primarili us europ
market
click detail financi
ertapenem like larg opportun
current aurobindo approv gener ertapenem brand
size mn wac price suggest aurobindo
launch ertapenem discount innov actual rebat
could higher still price rx show authoris
gener yet thu absenc new gener ertapenem per
quarter contribut mn sale assum market share
aurobindo
term competit known player ac dobfar got approv
april yet launch player litig earlier
hospira sandoz savior addit sun pharma file dmf
ertapenem januari could look opportun
sequent dmf june possibl
could involv well steadi state ertapenem
becom six gener market ertapenem could still good
aurobindo mn annual
therefor best case aurobindo gener
ertapenem mn per quarter opportun start
steadi state six gener market ertapenem
mn opportun may take year reach steadi
state ertapenem like great opportun auro
model mn sale auro ertapenem
reyatazlimit competit near term annualis
mn
gener reyataz mn brand size like good
opportun auro near term three gener
market current includ teva day exclus launch
decemb authoris gener aurobindo launch late
june number filer reyataz high expect
gener player includ cipla therefor
reyataz could annualis mn opportun
vancomycin injectionlik mn annualis
vancomycin inject launch expect auro eir
alreadi aurobindo alreadi approv vancomycin four
strength total market size mn im level two strength
name low competit gener market
size mn view vancomycin contribut mn
annualis sale auro assum market share
figur vancomycin like annualis aurobindo
gener market freseniu sagent
gener market freseniu sagent
gener market freseniu bluepoint
gener market freseniu bluepoint
over-the-counter franchis get boost omeprazol
ibuprofen launch
over-the-counter sale aurobindo alreadi got boost launch
nexium mucinex past quarter view current
over-the-counter sale mn annualis auro
omeprazol over-the-counter tablet market size mn ibuprofen
capsul launch septemb market
size mn product aurobindo potenti
make mn annualis sale
toprol-xl approv resumpt inject suppli
trigger
auro target action date toprol-xl anda septemb
also guid resumpt bag suppli inject
two help off-set potenti competit ertapenem
seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid
report singl factor make invest decis
compani mention price
anubhav aggarw certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
price rate histori aurobindo pharma ltd arbn bo
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attractiv neutral less attract
underperform least attract invest opportun octob canadian well european ra ting base stock total return
rel analyst coverag univers consist comp ani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan
australia rate base stock total return rel averag total return relev countri regio nal benchmark india bse sensex index
prior octob canadian rate base stock ab solut total return potenti current share price rel
attract stock total return potenti within analyst coverag univers australian new zealand stoc ks expect total return calcul
includ roll dividend yield outperform rate assign greater equal under-perform wh ere less
equal neutral may assign overlap rate rang allow analyst assign rate put
context associ risk prior may rang outperform under-perform rate overlap ne utral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
rate nr credit suiss equiti research invest rate view stock secur relat compani
time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view
equiti secur compani relat product
volatil indic stock defin volatil stock price move month least past
month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat
sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform close correspond
